Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

Index raises $2bn across three funds

2 min read
16:30UTC

Index Ventures announced $2bn of new capacity on 31 July in its own post, three days before the trade press reported it, taking total investing power to $3.5bn.

TechnologyDeveloping
Key takeaway

Index refilled seed, venture and growth funds at once, reaching $3.5bn of capacity.

Index Ventures raised $2bn across three new funds on 31 July, announced in its own post rather than the trade report that followed three days later⁠1. The breakdown is a $400m seed fund, a $900m venture fund, and a growth fund upsized by $700m to $2.2bn, giving The Firm $3.5bn of investing capacity across all stages.

Index refilled all three vehicles in a single announcement. Most firms refill one vehicle at a time, which leaves a stage uncovered for a year or more and pushes their own portfolio companies out to other investors at exactly the round where terms get set. A firm holding fresh capital at seed, venture and growth simultaneously can follow a company from a first cheque to a pre-IPO round without ever handing the lead to someone else.

British founders feel that as a practical change rather than a structural one. Index has been active in this market all year, co-leading Conduct's $60m Series A with ICONIQ in June and backing the Edinburgh legal-AI company Wordsmith. A growth vehicle of $2.2bn can price a British pre-IPO round without an American co-lead beside it, and the binding constraint on that has never been appetite so much as the size of the pool sitting on this side of the Atlantic.

Deep Analysis

In plain English

Index Ventures, a major venture capital firm, announced it raised $2bn split across three separate funds: a $400m fund for the earliest 'seed' investments, a $900m fund for more established 'venture' stage companies, and a growth fund that grew by $700m to $2.2bn for the biggest, latest-stage deals. Altogether, The Firm now has $3.5bn to invest across companies at every stage, from brand new to nearly ready to go public. Index posted this news itself on 31 July, three days before most trade outlets reported it, which is unusual: most fundraising news reaches readers through journalists first.

What could happen next?
  • Opportunity

    UK venture-stage companies gain a larger pool of follow-on capital from Index Ventures' upsized $900m fund.

First Reported In

Update #14 · UKRI's sponsor department no longer exists

Index Ventures· 24 Aug 2026
Read original →
Causes and effects
This Event
Index raises $2bn across three funds
One of the few firms that can lead a British round at every stage just refilled at every stage at once, which changes who a founder has to fly to New York to meet.
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.